Literature DB >> 1832806

Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs.

M Chengalvala1, M D Lubeck, A R Davis, S Mizutani, K Molnar-Kimber, J Morin, P P Hung.   

Abstract

Recombinant hepatitis B virus vaccines based on adenovirus (Ad) vectors Ad4 and Ad7 have been prepared. However, immunogenicity testing of such vaccines in experimental animals is difficult because these human adenoviruses exhibit a highly restricted host range. In this study, the dog was evaluated as a model for screening Ad4- and Ad7-vectored vaccines. Intratracheal inoculation of dogs with Ad4 and Ad7 induced substantial type-specific humoral immune responses that were significantly higher than responses obtained following pharyngeal or oral inoculations. Inoculation of dogs with recombinant Ad7 and Ad4 vaccines expressing hepatitis B surface antigen (HBsAg) elicited large antibody responses to HBsAg (anti-HBs). Substantial secondary anti-HBs responses were produced upon sequential immunizations with heterotypic Ad7 and Ad4 recombinant vaccines. These data thus indicate that the dog is a useful model for evaluating immune responses to vaccines based on Ad4 and Ad7 vectors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832806     DOI: 10.1016/0264-410x(91)90033-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.

Authors:  S L Buge; E Richardson; S Alipanah; P Markham; S Cheng; N Kalyan; C J Miller; M Lubeck; S Udem; J Eldridge; M Robert-Guroff
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Construction of an adenovirus type 7a E1A- vector.

Authors:  K Abrahamsen; H L Kong; A Mastrangeli; D Brough; A Lizonova; R G Crystal; E Falck-Pedersen
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 3.  Oral delivery of vaccines. Formulation and clinical pharmacokinetic considerations.

Authors:  D T O'Hagan
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

4.  Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.

Authors:  Michael Berg; Julie Difatta; Egbert Hoiczyk; Richard Schlegel; Gary Ketner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-14       Impact factor: 11.205

5.  Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

Authors:  S L Buge; L Murty; K Arora; V S Kalyanaraman; P D Markham; E S Richardson; K Aldrich; L J Patterson; C J Miller; S M Cheng; M Robert-Guroff
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  Vaccines within vaccines: the use of adenovirus types 4 and 7 as influenza vaccine vectors.

Authors:  Eric A Weaver
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

7.  Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.

Authors:  Zachary C Hartman; Daniel M Appledorn; Delila Serra; Oliver Glass; Todd B Mendelson; Timothy M Clay; Andrea Amalfitano
Journal:  Virology       Date:  2008-02-15       Impact factor: 3.616

Review 8.  Prospects for oral replicating adenovirus-vectored vaccines.

Authors:  Cailin Deal; Andrew Pekosz; Gary Ketner
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

9.  Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

Authors:  L Jean Patterson; Nina Malkevitch; Joel Pinczewski; David Venzon; Yuanmei Lou; Bo Peng; Cindy Munch; Melissa Leonard; Ersell Richardson; Kristine Aldrich; V S Kalyanaraman; George N Pavlakis; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.

Authors:  P W Chen; M Wang; V Bronte; Y Zhai; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.